Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
🩺 Plain-English Summary (8th-Grade Level)
This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis of invasive breast cancer, clinical stage tumor 1-3 (cT1-T3), node 0-3 (cN0-N3), metastasis 0 (cM0), hormone receptor positive (HR+) (estrogen-receptor-positive (ER+) and/or progesterone-receptor-positive (PR+) human epidermal growth factor receptor 2 (HER2) negative or hormone receptor-negative (HR-) (estrogen-receptor-negative (ER-) and progesterone-receptor-negative (PR-) human epidermal growth factor receptor 2 (HER2) negative/triple-negative breast cancer.
Who can join: Review the eligibility criteria below.
Location: Froedtert Hospital & Medical College of Wisconsin — Milwaukee, Wisconsin
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Froedtert Hospital & Medical College of Wisconsin — Milwaukee, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Invasive Breast Cancer
- Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions — Cleveland, Ohio
- Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC — Atlanta, Georgia
- Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer — New York, New York
- TRUDI: TDXD+Durva in HER2+/Low IBC — Boston, Massachusetts
- Sacituzumab Govitecan In TNBC — Boston, Massachusetts
Explore by condition: All Invasive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.